Navigation Links
Novel strategy stymies SARS et al.
Date:10/28/2011

ally at the virus itself," explains Professor Christian Drosten, Director of the Institute of Virology at Bonn University Hospital. "And since viral pathogens are highly diverse, each of these agents can attack only certain viruses." Moreover, viruses are also highly mutable, making the weaponry they can deploy against us even more powerful. What works against one viral strain may be essentially useless against another.

The SARS virus, a previously unknown pathogen which threatened to cause a worldwide pandemic in 2003, has spurred on the search for new antiviral substances. Only recently, it was shown that not only Chinese, but also European, bats carry the SARS virus. "But in contrast to the situation with bird influenza, one cannot simply kill these free-living animals in order to eradicate the pathogen," says Drosten. "That would have catastrophic ecological consequences and, apart from that, bats are retiring and secretive in their habits." If one wishes to develop drugs against viruses that can "hide" in animal species, one must explore other alternatives.

The research teams assembled by von Brunn and Drosten have now discovered a way to prevent the replication of a whole family of viruses by depriving them of an essential host factor. They first identified host proteins with which SARS viral proteins interact. This strategy led to the finding that a cellular signaling pathway is essential for the replication not only of the SARS virus, but also of a whole set of related viruses that are pathogenic to humans and animals.

"This signal pathway is normally involved in regulating the immune system," says Drosten. "We used a substance that inhibits the function of one of the proteins in the pathway, and found that it suppresses viral replication." In other words, drugs that block this pathway inhibit the replication of many different viruses, and therefore act as broad-spectrum antivirals. This opens a route to the treatment of conditi
'/>"/>

Contact: Dr. Kathrin Bilgeri
kathrin.bilgeri@lmu.de
49-218-06938
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Novel therapeutic target identified to decrease triglycerides and increase good cholesterol
2. Innovation at Regenstrief: Leveraging novel ideas to improve health care
3. Novel technique reveals both gene number and protein expression simultaneously
4. Novel research set to pinpoint risk of heart attacks and strokes
5. Novel cytokine protects mice from colitis
6. FDA Approves Novel Melanoma Drug
7. St. Michaels North America first to use novel blood-cleaning procedure for kidney transplant
8. Novel DNA sequencer for MDCs systems biology
9. Novel Virus Jumped From Monkeys to Humans, Researchers Find
10. Novel combined therapy extends life, diminishes pain in brain cancer patients
11. Experiment aboard shuttle Atlantis will test novel therapy to build bone during space travel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Laguna Hills, CA (PRWEB) February 27, 2015 ... has been chosen as their Sage ERP Document Management ... ERP, Sage 300 ERP, Sage CRM and other complimentary ... ADSS Global have worked side-by-side for many years to ... their Sage ERP applications. , “We are thrilled ...
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 On February ... “The Real Liquid Botox ,” that details the development ... that is working its way through FDA trials. For those ... cream is very attractive. Of course, if the drug ... prescription at a physician’s office. (see: goo.gl/PQvQwk) , “As the ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility ... (MMW) on the Upper East Side, was officially dedicated and ... His Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, ... and a member of the ArchCare Board of Trustees, presided ... O.Carm, executive director of MMW, and Christina McInerney, president and ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 The ... and research expertise have made it a beacon of ... and beyond, has been acknowledged by the national society ... the Huntington’s Disease Society of America — as ... , The acknowledgement recognizes the center’s service to over ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Is Topical Botox the Next Big Thing? 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... Diego, CA, August 2, 2011 Engaging in physical ... the odds of survival. In a study published in ... Preventive Medicine , researchers from the Israel Study Group ... (MI) survivors who lived in low socioeconomic status (SES) ...
... 29, 2011) − In a recent study published in ... University of Kentucky College of Nursing and Mark Pyles, ... at the College of Charleston, found smoke-free legislation does ... urban communities. This is true regardless of whether the ...
... -- Teens are much more likely to eat junk food ... with many fast food restaurants and other sources of unhealthy ... on junk food consumption by California teens living in neighborhoods ... food restaurants, convenience stores, dollar stores and liquor stores, with ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... after dinner. Play tag with your kids at the park. ... 150 minutes, or 2.5 hours, of moderate activity a week -- ... Those who did more -- about 300 minutes a week, ...
... Blocking a growth factor receptor cripples cancer growth in a ... online on August 1 in the Journal of Experimental ... cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic ... in aberrant activation of the cell. A study by Andrew ...
... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
Cached Medicine News:Health News:Heart attack survivors from poorer neighborhoods get less exercise 2Health News:Study finds smoke-free laws don't impact rural or urban economies 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:Even a Little Exercise Helps the Heart, Study Finds 2Health News:Even a Little Exercise Helps the Heart, Study Finds 3Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... DIEGO, Dec. 22, 2011 ViroPharma Incorporated (NASDAQ: ... exclusive option to acquire Meritage Pharma, Inc., a private company ... suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a ... has paid an initial $7.5 million, and has agreed to ...
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
Cached Medicine Technology:ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 2ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 4ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 5ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 6ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 7Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2
1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric...
... A-scan Sonomed-315 is intended for visualization of ... of midline shifts in the brain, evaluation ... easy to use, the Sonomed-315 offers quick ... mode allows to identify the anatomic structures ...
... a scaleable device that works ... platelet plasma or buffy coat. ... coat must be prepared independently ... Starting volume and concentration factor ...
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Medicine Products: